Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Historical Holders from Q3 2019 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
MIRM on Nasdaq
Shares outstanding
51,368,292
Price per share
$78.99
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
57,250,652
Total reported value
$4,197,044,283
% of total 13F portfolios
0.01%
Share change
+1,595,658
Value change
+$132,882,990
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
267
Price from insider filings
$80.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 11% +6% $388,340,181 +$31,912,348 5,445,039 +9% JANUS HENDERSON GROUP PLC 28 Nov 2025
Frazier Life Sciences IX, L.P. 7.4% 0% $273,828,978 3,735,220 0% James N. Topper 01 Nov 2025
EVENTIDE ASSET MANAGEMENT, LLC 5.4% $107,692,609 2,606,938 Eventide Asset Management, LLC 31 Dec 2024
BIOTECHNOLOGY VALUE FUND L P 3% $109,619,710 1,495,290 BVF PARTNERS L P/IL 30 Sep 2025
As of 30 Sep 2025, Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) has 267 institutional shareholders filing 13F forms. They hold 57,250,652 shares. .

Top 25 institutional shareholders own 75% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 13% 6,795,121 0% 15% $498,150,321
JANUS HENDERSON GROUP PLC 9.7% 4,997,586 -4.6% 0.17% $366,518,621
BlackRock, Inc. 7% 3,602,434 +0.71% 0% $264,094,437
VANGUARD GROUP INC 5% 2,545,369 -0.76% 0% $186,601,001
EVENTIDE ASSET MANAGEMENT, LLC 4.9% 2,522,563 -4.4% 3% $184,923,401
BVF INC/IL 2.9% 1,495,290 -46% 4.4% $109,619,710
STATE STREET CORP 2.6% 1,346,904 -2.1% 0% $98,741,532
PRICE T ROWE ASSOCIATES INC /MD/ 2.5% 1,283,288 -9.5% 0.01% $94,079,000
NOVO HOLDINGS A/S 2.5% 1,264,028 -16% 6% $92,665,893
TANG CAPITAL MANAGEMENT LLC 2.4% 1,236,027 0% 3.5% $90,613,139
CITADEL ADVISORS LLC 2% 1,040,544 -26% 0.06% $76,282,281
GEODE CAPITAL MANAGEMENT, LLC 2% 1,010,022 -1.9% 0% $74,056,868
Clearbridge Investments, LLC 2% 1,003,803 -2.3% 0.06% $73,588,785
D. E. Shaw & Co., Inc. 1.8% 923,509 +66% 0.05% $67,702,445
Polar Capital Holdings Plc 1.6% 820,552 -16% 0.29% $60,154,667
WELLINGTON MANAGEMENT GROUP LLP 1.5% 790,689 +567% 0.01% $57,965,410
Point72 Asset Management, L.P. 1.5% 790,675 +205% 0.13% $57,964,420
Rock Springs Capital Management LP 1.5% 761,126 -7% 3.3% $55,798,147
MORGAN STANLEY 1.3% 670,149 +18% 0% $49,128,631
LORD, ABBETT & CO. LLC 1.3% 661,940 -14% 0.14% $48,527,000
FMR LLC 1.2% 640,218 +977% 0% $46,934,414
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.2% 612,318 +709% 0.03% $44,889,033
Nuveen, LLC 1.2% 601,670 +1.9% 0.01% $44,108,428
FRANKLIN RESOURCES INC 1.2% 601,137 +1.3% 0.01% $44,069,353
BNP PARIBAS FINANCIAL MARKETS 1.2% 601,073 0% 0.03% $44,064,662

Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 28,395 $2,219,922 +$1,646,118 7,898.89% 8
2025 Q3 57,250,652 $4,197,044,283 +$132,882,990 7,331% 267
2025 Q2 55,393,029 $2,819,019,204 +$70,434,976 5,089% 211
2025 Q1 54,142,705 $2,443,759,313 +$49,081,267 4,505% 213
2024 Q4 52,986,109 $2,190,964,431 -$26,045,809 4,135% 204
2024 Q3 53,301,609 $2,079,251,226 -$2,890,149 3,900% 176
2024 Q2 53,362,791 $1,824,471,702 +$17,964,526 3,419% 157
2024 Q1 53,243,448 $1,337,601,222 +$70,337,692 2,512% 167
2023 Q4 50,259,606 $1,483,847,413 +$1,676,068 2,952% 184
2023 Q3 48,930,333 $1,545,592,030 +$398,674,334 3,160% 156
2023 Q2 36,937,639 $955,518,729 +$63,103,719 2,587% 143
2023 Q1 34,669,406 $832,753,531 +$33,992,984 2,402% 114
2022 Q4 33,331,988 $650,146,380 -$12,725,497 1,950% 101
2022 Q3 33,748,714 $709,089,633 +$93,197,315 2,101% 107
2022 Q2 29,289,263 $568,434,366 +$47,575,699 1,946.02% 104
2022 Q1 26,813,353 $590,437,915 -$6,195,298 2,202% 99
2021 Q4 22,891,220 $365,087,000 +$18,990,411 1,595% 81
2021 Q3 21,414,209 $426,514,254 +$2,080,056 1,992.02% 69
2021 Q2 21,482,092 $371,413,185 +$642,669 1,729% 66
2021 Q1 21,451,984 $425,174,000 -$8,433,468 1,981.98% 60
2020 Q4 22,010,623 $384,380,000 +$52,268,047 1,745.99% 71
2020 Q3 18,743,135 $361,180,000 -$1,290,295 1,927% 50
2020 Q2 18,808,446 $366,015,000 +$8,936,163 1,946.06% 57
2020 Q1 18,603,225 $260,445,000 +$32,083,278 1,400% 43
2019 Q4 16,248,910 $398,421,000 +$12,819,124 2,451.9% 39
2019 Q3 16,487,274 $165,856,000 +$165,755,000 1,005.69% 38